» Articles » PMID: 20232404

Evaluation of Local Recurrence After Treatment for Hepatocellular Carcinoma by Contrast-enhanced Ultrasonography Using Sonazoid: Comparison with Dynamic Computed Tomography

Overview
Specialty Radiology
Date 2010 Mar 17
PMID 20232404
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To evaluate the effectiveness of contrast-enhanced ultrasonography (CEUS) using Sonazoid for the diagnosis of the local recurrence after treatment for hepatocellular carcinoma (HCC) by comparing it with dynamic CT.

Methods: Seventy-one patients with 87 HCC lesions (mean +/- SD; 19.5 +/- 9.6 mm) underwent CEUS using Sonazoid and dynamic CT after radiofrequency ablation (n = 55), transcatheter arterial chemoembolization (n = 22), or radiofrequency ablation combined with transcatheter arterial chemoembolization (n = 10). Two hepatologists (observer 1; 10 years of experience, and 2; 20 years of experience) reviewed the CEUS and dynamic CT images independently and evaluated presence or absence of the local recurrence. Diagnostic performance for the local recurrence was assessed using receiver operating characteristic curve analysis.

Results: The Az value for dynamic CT was significantly lower in observer 1 than 2 (p < 0.05). The sensitivity of CEUS was 79% in observer 1 and 83.9% in observer 2, and that of dynamic CT was 83.9% and 90.3%, respectively. The specificity of CEUS was 96%, and that of dynamic CT was 92%, in both observers.

Conclusion: This study suggests that CEUS using Sonazoid is less affected by the observer's experience and is more accurate in the diagnosis of local recurrence after treatment for HCC than dynamic CT.

Citing Articles

Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.

Kudo M Liver Cancer. 2023; 12(4):289-296.

PMID: 37901198 PMC: 10601881. DOI: 10.1159/000532023.


Achievement of Complete Response and Drug-Free Status by Atezolizumab plus Bevacizumab Combined with or without Curative Conversion in Patients with Transarterial Chemoembolization-Unsuitable, Intermediate-Stage Hepatocellular Carcinoma: A....

Kudo M, Aoki T, Ueshima K, Tsuchiya K, Morita M, Chishina H Liver Cancer. 2023; 12(4):321-338.

PMID: 37901197 PMC: 10603621. DOI: 10.1159/000529574.


Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology.

Jeong W, Kang H, Choi S, Park M, Yu M, Kim B Korean J Radiol. 2023; 24(6):482-497.

PMID: 37271203 PMC: 10248355. DOI: 10.3348/kjr.2023.0324.


Letter to the editor on "Perfluorobutane contrast-enhanced ultrasonography for the diagnosis of HCC: a systematic review and meta-analysis".

Wu J, Ge L, Lu L Abdom Radiol (NY). 2021; 47(2):903-904.

PMID: 34748043 DOI: 10.1007/s00261-021-03338-8.


Meta-analysis and systematic review of contrast-enhanced ultrasound in evaluating the treatment response after locoregional therapy of hepatocellular carcinoma.

Hai Y, Savsani E, Chong W, Eisenbrey J, Lyshchik A Abdom Radiol (NY). 2021; 46(11):5162-5179.

PMID: 34410432 PMC: 8569603. DOI: 10.1007/s00261-021-03248-9.